ClinicalTrials.gg
RecruitingNCT04345627J-LEXUpdated Nov 12, 2026

Japanese Lead Extraction Registry

An observational study in Arrhythmia, Cardiac, sponsored by National Cerebral and Cardiovascular Center, Japan. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Cerebral and Cardiovascular Center, Japan · Observational

How we know

From the registry’s dates

  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Arrhythmias, Cardiac with a site in Japan — 6 open to participants now, 6 under way, none of them phase 3. Arrhythmias, Cardiac · Japan.

Planned enrollment
4th of 15
5,000 · median 1,604
Started
2018
with 2 others
Observational
15 of 23
4 open now
Registered
19th of 23
by date
Lead sponsor
2 of 23
National Cerebral and Cardiovascular Center, Japan

Among the 23 studies in Arrhythmias, Cardiac with a site in Japan, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2018, is one of 15 observational ones, and was the 19th registered.

Arrhythmias, Cardiac

1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

6 of the 23 studies in Arrhythmias, Cardiac with a site in Japan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Arrhythmias, Cardiac with a site in Japan, or all of them as a file.
02

Study summary

Japanese Lead Extraction (J-LEX) Registry is an observational nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The acute success rate at discharge and the complications associated with transvenous lead extraction will be collected. J-LEX registry will provide a reliable information on indications, methods, the success rate, complications and the prognosis at 30 days prognosis.

Read the detailed description

Japanese Lead Extraction (J-LEX) Registry is a nationwide, multicenter, observational registry, performed by Japanese Heart Rhythm Society, collaborated with National Cerebral and Cardiovascular Center. This study is a voluntary nationwide registry and data are collected prospectively using a Research Electronic Data Capture (REDCap) system until 30 days after the lead extraction. The investigators will collect the data regarding patient's background and lead characteristic, medical history, details about lead extraction procedure, lead characteristics, and outcomes. The data were anonymized in a linkable manner at each study site before they were sent. Based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the event assessment committee.

03

Conditions studied

  • Arrhythmia, Cardiac

Keywords

  • Lead extraction
  • Pacemaker
  • Defibrillator
  • Complication
  • REDCap
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing transvenous lead extraction in Japan.

Exclusion criteria

Exclusion Criteria:

  • Patients who receive open-chest surgical extraction alone.
  • Patients who refused to consent.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Proportion of procedural success

    Procedural success was defined as complete or partial and is identified for each lead extracted.

    Time frame: Through discharge from hospital, approximately up to 2 weeks.

Secondary outcomes

  1. Number of in-hospital deaths

    All-cause death, cardiovascular death, and procedure-related death

    Time frame: Through discharge from hospital, approximately up to 2 weeks.

  2. Number of patients with procedure-related complications

    Bleeding events, embolic events, other all complications. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Mar 2032, 164 months after the start.

Of 190 non-industry observational studies under Arrhythmias, Cardiac, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 140. This study's planned 164 months is above that.

Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2020
First posted
Apr 14, 2020
StartActual
Jul 1, 2018
Primary completionEst.
Mar 31, 2032
CompletionEst.
Mar 31, 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04345627
Lead sponsor
National Cerebral and Cardiovascular Center, Japan
Responsible party
Kengo Kusano (Director of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, National Cerebral and Cardiovascular Center, Japan) — Principal investigator
First posted
Apr 14, 2020
Start date
Jul 1, 2018
Primary completion
Mar 31, 2032 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Kengo Kusano, MD, PhD
Contact
kusanokengo@ncvc.go.jp
+81-6-6170-1070
Misa Takegami, PhD, MPH
Contact
takegami@ncvc.go.jp
+81-6-6170-1070
Kengo Kusano, MD, PhD
principal investigator · National Cerebral and Cardiovascular Center, Japan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion